Breaking News

Roche’s MabThera Launch Triggers $5M Halozyme Milestone

June 25, 2014

Marks second product to use Halozyme's Enhanze technology

Roche’s MabThera SC has launched in Europe, triggering a $5 million milestone payment to Halozyme Therapeutics under the companies’ license and collaboration agreement. In addition to Herceptin SC, MabThera SC is the second subcutaneous formulation of one of Roche's oncology products to use Halozyme's Enhanze (recombinant human hyaluronidase) technology.
MabThera SC is approved for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. This formulation could potentially save time for patients, physicians and health care providers.
blog comments powered by Disqus
  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • Talking Trends with Aesica

    Talking Trends with Aesica

    Tim Wright, editor||February 26, 2016
    Managing director Ian Muir fills us in on the latest at the CDMO